Discover your next big idea for life sciences at PACK EXPO Las Vegas
Experience a breakthrough in life sciences packaging—explore solutions from 2,300 suppliers spanning all industries, all in one place this September

TricorBraun Names New Chief Financial Officer

TricorBraun has named Charles J.

Pfister chief financial officer, according to Keith J. Strope, company president and chief executive officer. Mr. Pfister will be responsible for the firm's finance, corporate administration and human resource groups. He will be based in the firm's St. Louis headquarters.

TricorBraun, with sales of almost $1 billion, is one of North America's largest providers of jars, bottles and other rigid packaging components.

Prior to joining TricorBraun, he had been senior vice president of finance for Kohl's Corporation, (NYSE:KSS). At Kohl's, Mr. Pfister was responsible for financial planning and analysis as well as the company's treasury, tax and investor relations departments. He was employed at Kohl's from 2008 to 2012.

From 2001 to 2008, Mr. Pfister was a vice president for The Home Depot (NYSE: HD) and was most recently in charge of corporate financial planning and analysis and indirect procurement.

Mr. Pfister graduated from the University of Illinois, Urbana, in 1987 where he earned a Bachelor of Science degree in economics with an emphasis in accounting. He became a Certified Public Accountant in 1989.
Pharmaceutical Innovations Report
Discover the latest breakthrough packaging technologies shaping the pharmaceutical sector. This report dives into cutting-edge innovations, from smart containers that enhance patient safety to eco-friendly materials poised to transform the industry’s sustainability practices. All from PACK EXPO. Learn how forward-thinking strategies are driving efficiency and redefining what’s possible in pharma packaging.
Learn More
Pharmaceutical Innovations Report
FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
FDA warning letters surge - is your team prepared?